153 related articles for article (PubMed ID: 38354416)
1. Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates.
Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Tang S; Protopopova M; Kelleher E; Jones B; Yang L; Custar D; Catcott KC; Demady DR; Collins SD; Xu L; Bu C; Qin L; Ter-Ovanesyan E; Damelin M; Toader D; Lowinger TB
Mol Cancer Ther; 2024 Apr; 23(4):541-551. PubMed ID: 38354416
[TBL] [Abstract][Full Text] [Related]
2. A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs).
Miller ML; Shizuka M; Wilhelm A; Salomon P; Reid EE; Lanieri L; Sikka S; Maloney EK; Harvey L; Qiu Q; Archer KE; Bai C; Vitharana D; Harris L; Singh R; Ponte JF; Yoder NC; Kovtun Y; Lai KC; Ab O; Pinkas J; Keating TA; Chari RVJ
Mol Cancer Ther; 2018 Mar; 17(3):650-660. PubMed ID: 29440292
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates.
Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Gumerov DR; Tang S; Kelleher E; Jones BD; Protopopova M; Qin L; Uttard A; Demady DR; Lowinger TB
Bioorg Med Chem Lett; 2022 Sep; 72():128876. PubMed ID: 35788036
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.
Tiberghien AC; Vijayakrishnan B; Esfandiari A; Ahmed M; Pardo R; Bingham J; Adams L; Santos K; Kang GD; Pugh KM; Afif-Rider S; Vashisht K; Haque K; Tammali R; Rosfjord E; Savoca A; Hartley JA; Howard PW
Mol Cancer Ther; 2023 Feb; 22(2):254-263. PubMed ID: 36722141
[TBL] [Abstract][Full Text] [Related]
5. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates.
Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA
Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs).
Reid EE; Archer KE; Shizuka M; McShea MA; Maloney EK; Ab O; Lanieri L; Wilhelm A; Ponte JF; Yoder NC; Chari RVJ; Miller ML
Bioorg Med Chem Lett; 2019 Sep; 29(17):2455-2458. PubMed ID: 31350125
[TBL] [Abstract][Full Text] [Related]
7. Payload diversification: a key step in the development of antibody-drug conjugates.
Conilh L; Sadilkova L; Viricel W; Dumontet C
J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546
[TBL] [Abstract][Full Text] [Related]
8. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
9. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
10. A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.
Miller ML; Fishkin NE; Li W; Whiteman KR; Kovtun Y; Reid EE; Archer KE; Maloney EK; Audette CA; Mayo MF; Wilhelm A; Modafferi HA; Singh R; Pinkas J; Goldmacher V; Lambert JM; Chari RV
Mol Cancer Ther; 2016 Aug; 15(8):1870-8. PubMed ID: 27216304
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.
Weng W; Meng T; Zhao Q; Shen Y; Fu G; Shi J; Zhang Y; Wang Z; Wang M; Pan R; Ma L; Chen C; Wang L; Zhou B; Zhang H; Pu J; Zhang J; Hu YP; Hua G; Qian Y; Liu SH; Hu W; Meng X
Cancer Discov; 2023 Apr; 13(4):950-973. PubMed ID: 36693125
[TBL] [Abstract][Full Text] [Related]
13. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
14. Antibody drug conjugates beyond cytotoxic payloads.
Hobson AD
Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
[TBL] [Abstract][Full Text] [Related]
15. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
[TBL] [Abstract][Full Text] [Related]
16. DNA sequence-selective G-A cross-linking ADC payloads for use in solid tumour therapies.
Procopiou G; Jackson PJM; di Mascio D; Auer JL; Pepper C; Rahman KM; Fox KR; Thurston DE
Commun Biol; 2022 Jul; 5(1):741. PubMed ID: 35906376
[TBL] [Abstract][Full Text] [Related]
17. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
18. Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates.
Khera E; Dong S; Huang H; de Bever L; van Delft FL; Thurber GM
Mol Cancer Ther; 2022 Feb; 21(2):310-321. PubMed ID: 34911819
[TBL] [Abstract][Full Text] [Related]
19. A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy.
Böhnke N; Berger M; Griebenow N; Rottmann A; Erkelenz M; Hammer S; Berndt S; Günther J; Wengner AM; Stelte-Ludwig B; Mahlert C; Greven S; Dietz L; Jörißen H; Barak N; Bömer U; Hillig RC; Eberspaecher U; Weiske J; Giese A; Mumberg D; Nising CF; Weinmann H; Sommer A
Bioconjug Chem; 2022 Jun; 33(6):1210-1221. PubMed ID: 35658441
[TBL] [Abstract][Full Text] [Related]
20. Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies.
Valsasina B; Orsini P; Caruso M; Albanese C; Ciavolella A; Cucchi U; Fraietta I; Melillo N; Fiorentini F; Rizzi S; Salsa M; Isacchi A; Gasparri F
Mol Cancer Ther; 2023 Dec; 22(12):1465-1478. PubMed ID: 37722716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
